ライフサイエンスコーパス: hydralazine

1 ltransferase expression (U0126, PD98059, and hydralazine).

2 drug-induced lupus, similar to the effect of hydralazine.

3 Ci = 37 GBq) with or without the vasodilator hydralazine.

4 y losartan or by the nonspecific vasodilator hydralazine.

5 en blood pressure is normalized with chronic hydralazine.

6 the augmentation of hyperthermic effects by hydralazine.

7 protein kinase (PKA) as the direct target of hydralazine.

8 4.7 1.1%, and 85.6 0.7% respectively without hydralazine.

9 n hypoxia induced by the vasomodulator agent hydralazine.

10 s induced by the ACE-independent vasodilator hydralazine.

11 in various other known beneficial effects of hydralazine.

12 s and the impact of isosorbide dinitrate and hydralazine.

13 Controls received water or hydralazine.

14 igration in vitro with losartan but not with hydralazine.

15 athway inhibitors including procainamide and hydralazine.

16 agen prolyl hydroxylase is a known target of hydralazine.

17 ssure was returned to control by infusion of hydralazine (0.01 to 0.06 mg.kg(-1).min(-1)), RSNA retur

18 Hydralazine (10 mg/kg i.v.) increased the number of Fos-

19 nal studies, we found that acute addition of hydralazine (10 microM) to nitroglycerin-tolerant vessel

20 Coexposure to hydralazine (10-100 muM) strongly suppressed cell ATP lo

21 in the group given isosorbide dinitrate plus hydralazine (10.2 percent vs. 6.2 percent, P=0.02).

22 ) was significantly higher than that without hydralazine (137.7 10.7 min).

23 either losartan (25 mg x kg(-1) x d(-1)) or hydralazine (15 mg x kg(-1) x d(-1)), both of which prev

24 ensive agents losartan (25 mg/kg per day) or hydralazine (15 mg/kg per day) inhibited this upregulati

25 etalol (48%), followed by nicardipine (15%), hydralazine (15%), and sodium nitroprusside (13%).

26 dose delivered by ultrasound treatment with hydralazine (170.8 11.8 min) was significantly higher th

27 by blood pressure elevation, we administered hydralazine (250 mg/L) in the drinking water.

28 male apoE/eNOS DKO mice that were not given hydralazine (28.3+/-3.1%, n=9).

29 n, which was again blocked by treatment with hydralazine (382+/-18% and 150+/-30% of the control leve

30 or without an intravenous administration of hydralazine (5 mg/kg).

31 RB; olmesartan, 5 mg/d) or a triple therapy (hydralazine 7.5 mg/d, reserpine 0.15 mg/d, and hydrochlo

32 s in forearm blood flow (CNP+, 93.0+/-14.8%; hydralazine+, 84.2+/-22.6%).

33 with aliskiren (a renin inhibitor), but not hydralazine (a smooth muscle relaxant), ameliorated coli

34 However, when RenTgMK mice were treated with hydralazine (a smooth muscle relaxant), the blood pressu

35 1) blocker; AT(1)), enalapril (an ACEI), and hydralazine (a vasodilator) were administered to spontan

36 lar decrease in SBP due to administration of hydralazine, a drug devoid of PDE inhibitory effect, did

37 eventable by normalizing blood pressure with hydralazine, a peripherally acting vasodilator.

38 t knockout of Dnmt1 and targeting DNMT1 with hydralazine, a safe demethylating agent, delays cyst gro

39 Hydralazine, a widely used therapy for hypertension and

40 cases of ANCA-GN complicating treatment with hydralazine, accounting for 4.3% (80/1858 biopsies) of A

41 Hydralazine activated more neurons than 2-deoxyglucose b

42 Thus, hydralazine activates the HIF pathway through inhibition

43 were treated with the antihypertensive agent hydralazine administered in the drinking water beginning

44 r last dose, offspring started receiving VPA/hydralazine administered via drinking water: no adverse

45 Hydralazine administration in animals caused a decrease

46 cerin patches (1.5 micrograms/kg/min x 3 d), hydralazine alone (10 mg/kg/d in drinking water), or hyd

47 CNP alone and hydralazine alone caused similar increases in forearm bl

48 Hydralazine also protects mitochondrial metabolism and f

49 astly, we show that the clinical response to hydralazine, an acute antihypertensive, is dosing time-d

50 Hydralazine, an antihypertensive agent, has displayed ne

51 it remains unknown whether continuous use of hydralazine-an antihypertensive agent (AHA) with notable

52 (33%) of the 30 patients had been exposed to hydralazine and 3 (10%) had been exposed to propylthiour

53 ctrum DNA methyltransferase (DNMT) inhibitor hydralazine and histone deacetylase (HDAC) inhibitor val

54 ood pressure normalization by treatment with hydralazine and hydrochlorothiazide prevented angiotensi

55 With discontinuation of hydralazine and immunosuppression, outcomes are similar

56 Although the combined use of hydralazine and isosorbide dinitrate confers important c

57 ine alone (10 mg/kg/d in drinking water), or hydralazine and nitroglycerin.

58 s represents a novel mechanism of action for hydralazine and presents HIF as a potential target for t

59 The vasodilator hydralazine and the AT1 receptor antagonist losartan had

60 Hydralazine and zofenopril reduced mean arterial pressur

61 es, NEH (a combination of norepinephrine and hydralazine) and Sanguinate (pegylated bovine carboxyhem

62 d propofol, fentanyl, metoprolol, lorazepam, hydralazine, and furosemide.

63 iple antihypertensive drugs (TRX; reserpine, hydralazine, and hydrochlorothiazide in drinking water;

64 Nitroprusside, adenosine, hydralazine, and nifedipine had no significant effect.

65 T cells treated with procainamide, hydralazine, and other Dnmt and ERK pathway inhibitors c

66 Some of these agents, such as procainamide, hydralazine, and UV-light inhibit T cell DNA methylation

67 Procainamide and hydralazine are drugs that cause lupus in genetically pr

68 ant site-level differences, particularly for hydralazine, ARNI, devices, and cardiac rehabilitation.

69 ood pressure was controlled with intravenous hydralazine as needed.

70 Thus, hydralazine-associated ANCA-GN often exhibits overlappin

71 coinfusion of CNP at 500 pmol/min (n=8) and hydralazine at 10 microgram/min (n=8) (as a nonspecific

72 We have previously shown that hydralazine attacks carbonyl-adducted proteins in an "ad

73 ight not elucidate the protracted effects of hydralazine beyond a 12-month period.

74 clinically available anti-hypertensive agent hydralazine, both normalize aortic growth in Marfan mice

75 largely catecholaminergic, were activated by hydralazine but not saline.

76 When given concomitantly with nitroglycerin, hydralazine completely prevented the development of nitr

77 tor enalapril, but not the anti-hypertensive hydralazine, decreased pulmonary neutrophil recruitment

78 ering blood pressure to the same degree with hydralazine did not abolish the upregulation of TR mRNA

79 In vitro, hydralazine did not inhibit DNMT activity.

80 Additionally, hydralazine did not reduce expression levels of either t

81 Hydralazine did not significantly inhibit the effect of

82 the combination of isosorbide dinitrate and hydralazine differs in black and white heart failure coh

83 Reduction of hypertension with hydralazine does not change the prevalence of aggression

84 Hydralazine dose-dependently inhibited PHD activity and

85 We demonstrate that hydralazine extends healthy lifespan ( 25%) in wild type

86 dose combination of isosorbide dinitrate and hydralazine (FDC I/H) in patients with heart failure (HF

87 dose combination of isosorbide dinitrate and hydralazine (FDC-I/H) reduced mortality by 43% and death

88 with Ang II receptor antagonist losartan or hydralazine for 12 wk.

89 gual and transdermal nitrates, low-dose oral hydralazine for 48 hours, and rapid up-titration of angi

90 Over three-fourths of patients were on hydralazine for at least one year, with mean daily dose

91 ne prescription duration: an exposure group (hydralazine >=180 days; n = 59,786) and a reference grou

92 onths of therapy with either zofenopril (Z), hydralazine (H), or water (W).

93 c cross clamp: phentolamine mesylate (PM) or hydralazine (H).

94 One of the patients exposed to hydralazine had also been exposed to allopurinol.

95 Hydralazine has been recently shown to promote lifespan

96 Hydralazine has been shown to reduce mortality in patien

97 in vivo models, we go on to demonstrate that hydralazine has neuroprotective properties against endog

98 upus or treated with the lupus-inducing drug hydralazine have defective ERK phosphorylation.

99 ey'll be randomly assigned to receive either hydralazine HCL (25 mg, thrice daily) or a placebo for 1

100 rt failure rats, to test the hypothesis that hydralazine (HYD) alone or in combination with nitroglyc

101 mpared the effects of procainamide (Pca) and hydralazine (Hyd) with those of structural analogs, to d

102 dose combination of isosorbide dinitrate and hydralazine hydrochloride (FDC I/H) significantly decrea

103 In 2005, the combination of hydralazine hydrochloride and isosorbide dinitrate was a

104 n (FDA) approval of the fixed combination of hydralazine hydrochloride, 37.5 mg, and isosorbide dinit

105 trials showed little or no overall effect of hydralazine hydrochloride-isosorbide dinitrate in the mo

106 ally mixed patient populations that compared hydralazine hydrochloride-isosorbide dinitrate with plac

107 d black patients with heart failure who took hydralazine hydrochloride-isosorbide dinitrate with stan

108 Hydralazine (HYZ), a treatment for preeclampsia and hype

109 study, we found that the acrolein scavenger hydralazine (HZ), when applied from the day of induction

110 Previous trials testing isosorbide dinitrate/hydralazine (I/H) were performed in all-male study cohor

111 explore the potential benefits and risks of hydralazine in mild to moderate AD treatment.

112 yperthermia can be enhanced significantly by hydralazine in murine HCC tumors by modulating tumor blo

113 Treatment with hydralazine in rabbits not receiving nitroglycerin signi

114 RF, CRF antagonist D-PheCRF12-41 and chronic hydralazine in stress-induced cardiovascular responses.

115 Male apoE/eNOS DKO mice were treated with hydralazine in their drinking water (250 mg/L) using a d

116 the effect of lowering blood pressure using hydralazine in this diabetic eNOSKO mouse model.

117 ol mice not exposed to HF diet in utero, VPA/hydralazine increased mammary tumor incidence and burden

118 In sponge angiogenesis assays, hydralazine increased stromal cell infiltration and bloo

119 In vivo, hydralazine induced HIF-1alpha and VEGF protein in tissu

120 ification, is implicated in procainamide and hydralazine induced lupus, as well as idiopathic lupus.

121 Hydralazine induced rapid and transient expression of HI

122 by FG-labeled RVLM neurons after 2 hours of hydralazine-induced hypotension (to 73 +/- 2 mm Hg) in c

123 unanesthetized rats subjected to 2 hours of hydralazine-induced hypotension contained tenfold more c

124 Hydralazine-induced lupus could be caused in part by ind

125 tribute to the development of idiopathic and hydralazine-induced lupus through effects on T cell DNA

126 Instead, hydralazine inhibited ERK pathway signaling, thereby dec

127 tive DNA methyltransferase (Dnmt) inhibitor, hydralazine inhibits ERK pathway signaling thereby decre

128 of the ultrasound-treated tumors showed that hydralazine injection formed larger hemorrhagic pools an

129 Here, we report that the FDA approved drug hydralazine is a bona fide activator of the NRF2/SKN-1 s

130 Hydralazine is an FDA-approved drug used in the treatmen

131 xed-dose combination of isosorbide dinitrate/hydralazine (ISDN/HYD) improved clinical outcomes in the

132 In clinical trials, hydralazine-isosorbide dinitrate (H-ISDN) for heart fail

133 none in 2003 and a fixed dose combination of hydralazine-isosorbide dinitrate in 2005.

134 enalapril decreased overall mortality versus hydralazine/isosorbide dinitrate (p < 0.035) in V-HeFT I

135 Ivabradine and hydralazine/isosorbide dinitrate also have a role in the

136 ne antagonists in 24.1% (87.4% of eligible), hydralazine/isosorbide dinitrate in 8.6% (93.1% of eligi

137 razosin and placebo therapy in V-HeFT I, and hydralazine/isosorbide dinitrate was compared with enala

138 cular ejection fraction >35%, treatment with hydralazine/isosorbide dinitrate was compared with prazo

139 ers, beta-blockers, aldosterone antagonists, hydralazine/isosorbide dinitrate, and anticoagulants.

140 all mortality and sudden death compared with hydralazine/isosorbide dinitrate.

141 sed agents include nitroprusside, diazoxide, hydralazine, labetalol, esmolol, nicardipine, nifedipine

142 abilization of a catalytic subunit of PKA by hydralazine lead to improved mitochondrial function and

143 and hydralazine-treated cells revealed that hydralazine likely promoted Hsp90 migration from cytosol

144 180 days; n = 59,786) and a reference group (hydralazine <180 days; n = 239,144) after 1:4 matching f

145 Hydralazine markedly enhanced ultrasound hyperthermia th

146 Our data suggest that hydralazine may be a viable candidate for the treatment

147 y hydralazine, providing a mechanism whereby hydralazine may prevent tolerance.

148 We sought to determine mechanisms whereby hydralazine may prevent tolerance.

149 We show that hydralazine-mediated lifespan extension is SKN-1 depende

150 culprits receiving attention of late, namely hydralazine, minocycline, propylthiouracil (PTU) and lev

151 Hydralazine, minocycline, propylthiouracil and levamisol

152 ion, has been observed during treatment with hydralazine, nifedipine and ACE inhibitors.

153 short-term administration of nitroprusside, hydralazine, nifedipine or an angiotensin-converting enz

154 nhibitor (ARNI) use decreased over time, and hydralazine/nitrate use in eligible Black patients (19.3

155 ed beta-blocker use, aldosterone-antagonist, hydralazine/nitrate; p < 0.05) except warfarin in patien

156 ers, beta-blockers, aldosterone antagonists, hydralazine/nitrates, statin therapy, and warfarin), use

157 When hypotension was induced with hydralazine, NK3-R internalization was observed within 5

158 Long-term administration of hydralazine normalized blood pressure in NOS3(-/-) mice,

159 The effect of hydralazine on DNMT was tested in vitro using enzyme inh

160 ixed combination of isosorbide dinitrate and hydralazine on the primary composite end point (p = 0.01

161 Murine T cells treated with hydralazine or an ERK pathway inhibitor were injected in

162 ve a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addition to standard therapy f

163 now many reports that treatment with either hydralazine or propylthiouracil is associated with ANCA-

164 associated, especially following exposure to hydralazine or propylthiouracil.

165 medulla, in Sprague Dawley rats treated with hydralazine or saline.

166 e mice BH(4) (5 mg/d), but not treating with hydralazine or tetrahydroneopterin, improved cardiac BH(

167 treatment with either enalapril, furosemide, hydralazine, or losartan were all effective in reducing

168 ension were divided into two groups based on hydralazine prescription duration: an exposure group (hy

169 Hydralazine prevented the development of hypertension in

170 Hydralazine prevented the hypertension and abrogated the

171 we determined the prevalence of exposure to hydralazine, propylthiouracil, and other drugs previousl

172 ver, there have been reports suggesting that hydralazine, propylthiouracil, and several other drugs m

173 increased pulsatile load in SHR treated with hydralazine, provided a hemodynamic basis for the differ

174 fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with a

175 the activity of this oxidase is inhibited by hydralazine, providing a mechanism whereby hydralazine m

176 Compared with water or hydralazine, RAAS inhibition significantly increased the

177 Although the nucleophilic vasodilatory drug hydralazine readily traps such species under "test-tube"

178 VPA/hydralazine reduced mammary tumor multiplicity and lengt

179 Hydralazine reproduces the lupus ERK pathway signaling a

180 (not Wistar-Furth rats) being treated with a hydralazine-reserpine-hydrochlorothiazide regimen.

181 le-blind, placebo-controlled trial to assess hydralazine's effects on cognitive function in mild to m

182 his inaugural human clinical trial evaluates hydralazine's impact on patients in the mild to moderate

183 is via the SIRT1/SIRT5 axis, which underlies hydralazine's prolongevity and stress resistance benefit

184 Most strikingly, hydralazine selectively boosted the levels of cytoskelet

185 sion of established atherosclerosis, whereas hydralazine showed no benefit despite similar decrease i

186 Ultrasound treatment with hydralazine significantly reduced peak enhancement (PE),

187 l, carvedilol, digoxin, isosorbide dinitrate-hydralazine, spironolactone, and epleronone) for patient

188 in the group given isosorbide dinitrate plus hydralazine than in the placebo group (-0.1+/-1.9 vs. -0

189 te group than in the nimodipine group needed hydralazine to control blood pressure (54.3 percent vs.

190 This study investigates the use of hydralazine to enhance ultrasound hyperthermia for the t

191 The ability of hydralazine to inhibit vascular .O2- anion production re

192 ms were due to hypertension, we administered hydralazine to male apoE/eNOS DKO mice to reduce blood p

193 ated with angiotensin II and the vasodilator hydralazine to prevent hypertension showed defective glu

194 of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy for heart failure includ

195 +) lupus T cells as well as procainamide and hydralazine treated T cells, and contributes to excessiv

196 Biochemical fractionation of acrolein- and hydralazine-treated cells revealed that hydralazine like

197 4(+) T cells from patients with lupus and in hydralazine-treated cells.

198 Four of 11 hydralazine-treated male apoE/eNOS DKO mice developed ab

199 None of these benefits was observed in the hydralazine-treated mice despite equivalent reduction in

200 ignificantly reduced in samples derived from hydralazine-treated SHR as compared with those from hydr

201 Hydralazine-treated SHR had increased characteristic imp

202 CRF given to hydralazine-treated SHRLJ did not unmask a bradycardia.

203 and CD70 overexpression similar to lupus and hydralazine-treated T cells.

204 Hydralazine-treated, normotensive male apoE/eNOS DKO mic

205 zine-treated SHR as compared with those from hydralazine-treated, or untreated WKY.

206 Hydralazine treatment (4-5 weeks) prevented the developm

207 ncta in the NTS was significantly reduced by hydralazine treatment in the SHR model.

208 Comparable reduction in blood pressure by hydralazine treatment provided no such protection.

209 Hydralazine treatment significantly blocked the developm

210 enoprotective effects were not observed with hydralazine treatment, despite a similar antihypertensiv

211 trengthened by similar results obtained with hydralazine treatment, which inhibits expression of DNA

212 ady upregulated in HF offspring prior to VPA/hydralazine treatment.

213 We assess the association between hydralazine use and the risk of hematologic neoplasms us

214 In this study, we observed that long-term hydralazine use in patients with hypertension was associ

215 The vasodilator hydralazine, used clinically in cardiovascular therapy,

216 In Group I, class I antiarrhythmic drugs and hydralazine vasodilator therapy were routinely allowed.

217 yte width increased after MI, whether or not hydralazine was administered.

218 Hydralazine was ineffective in reducing cell size but ar

219 Lisinopril, dapagliflozin, and hydralazine were administered in drinking water starting

220 ying drugs nicotinamide, pentoxifylline, and hydralazine were used to manipulate tumor perfusion befo

221 , some beta-blockers, and the combination of hydralazine with nitrates have improved survival.

222 safety of the combined use of ultrasound and hydralazine would enable the clinical translation of the